The immunology of multiple sclerosis
KE Attfield, LT Jensen, M Kaufmann… - Nature Reviews …, 2022 - nature.com
Our incomplete understanding of the causes and pathways involved in the onset and
progression of multiple sclerosis (MS) limits our ability to effectively treat this complex …
progression of multiple sclerosis (MS) limits our ability to effectively treat this complex …
Multiple sclerosis progression: time for a new mechanism-driven framework
Traditionally, multiple sclerosis has been categorised by distinct clinical descriptors—
relapsing-remitting, secondary progressive, and primary progressive—for patient care …
relapsing-remitting, secondary progressive, and primary progressive—for patient care …
A lymphocyte–microglia–astrocyte axis in chronic active multiple sclerosis
Multiple sclerosis (MS) lesions that do not resolve in the months after they form harbour
ongoing demyelination and axon degeneration, and are identifiable in vivo by their …
ongoing demyelination and axon degeneration, and are identifiable in vivo by their …
2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis
MP Wattjes, O Ciccarelli, DS Reich, B Banwell… - The Lancet …, 2021 - thelancet.com
Summary The 2015 Magnetic Resonance Imaging in Multiple Sclerosis and 2016
Consortium of Multiple Sclerosis Centres guidelines on the use of MRI in diagnosis and …
Consortium of Multiple Sclerosis Centres guidelines on the use of MRI in diagnosis and …
[HTML][HTML] CNS remyelination and inflammation: From basic mechanisms to therapeutic opportunities
RJM Franklin, M Simons - Neuron, 2022 - cell.com
Remyelination, the myelin regenerative response that follows demyelination, restores
saltatory conduction and function and sustains axon health. Its declining efficiency with …
saltatory conduction and function and sustains axon health. Its declining efficiency with …
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial
Background Tolebrutinib is an oral, CNS-penetrant, irreversible inhibitor of Bruton's tyrosine
kinase, an enzyme expressed in B lymphocytes and myeloid cells including microglia, which …
kinase, an enzyme expressed in B lymphocytes and myeloid cells including microglia, which …
Ageing and multiple sclerosis
The factor that is most relevant and strongly associated with the clinical course of multiple
sclerosis is chronological age. Very young patients exclusively have relapsing remitting …
sclerosis is chronological age. Very young patients exclusively have relapsing remitting …
Microglia in multiple sclerosis: Protectors turn destroyers
VW Yong - Neuron, 2022 - cell.com
Microglia are implicated in all stages of multiple sclerosis (MS). Microglia alterations are
detected by positron emission tomography in people living with MS prior to the formation of …
detected by positron emission tomography in people living with MS prior to the formation of …
Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis
In contrast to the multiple disease-modifying therapies that are available for relapsing–
remitting multiple sclerosis (MS), the therapeutic options for progressive MS (PMS) are …
remitting multiple sclerosis (MS), the therapeutic options for progressive MS (PMS) are …
Advances in neurodegenerative diseases
J Van Schependom, M D'haeseleer - Journal of clinical medicine, 2023 - mdpi.com
Neurological disorders are the leading cause of physical and cognitive disability across the
globe, currently affecting approximately 15% of the worldwide population [1]. Absolute …
globe, currently affecting approximately 15% of the worldwide population [1]. Absolute …